NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Savara Inc. SVRA
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-0.53
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-63.5%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 19-year series below
Revenue
Net income
Per share
USD -0.53
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-63.5%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-51.0%
Each USD of equity lost 63 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+36.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+36.6%
−6.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.20B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 253.4M
total assets, end of FY2025
Total assetsUSD 253.4M
EquityUSD 203.1M
CashUSD 33.2M
Gross debtUSD 29.9M
Net debtUSD -3.3M
Current ratio11.85×
The company holds more cash than debt.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
·
·
·
·
·
0.0
0.0
·
0.0
0.0
0.0
0.0
0.0
0.0
·
0.0
·
·
·
Operating income $B
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
EBITDA $B
·
·
·
·
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
·
−0.0
−0.0
−0.0
·
·
·
·
Income tax $B
0.0
0.0
·
·
·
·
·
−0.0
−0.0
−0.0
0.0
0.0
0.0
·
·
·
·
·
·
Net income $B
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.53
−0.48
−0.33
−0.25
−0.32
−0.84
−1.95
−1.85
−1.76
−5.62
−9.48
−0.23
−0.28
−0.33
−0.47
−1.07
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−63.5
−61.5
−44.1
−30.2
−41.2
−59.7
−74.5
−54.1
−71.4
·
·
−194.5
−47.9
−31.6
−31.8
−50.7
−178.8
−143.9
−71.3
Shares out B
0.20
0.17
0.14
0.11
0.11
0.05
0.05
0.04
0.03
0.00
0.16
0.16
0.10
0.05
0.05
0.02
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
46 of 46
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed